These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Subscribe To Our Newsletter & Stay Updated
